SHANGHAI, China – Chinese biopharmaceutical companies are unlikely to benefit much from a relaxation in an 8-month-old ban on new initial public offerings (IPOs) or from new draft regulations aimed at improving disclosures and governance.

SHANGHAI, China – A licensing agreement may help troubled Israeli firm Biolinerx Ltd. get a toehold in China with its hepatitis C virus (HCV) treatment BL-8030.

SHANGHAI, China – A licensing agreement may help troubled Israeli Biolinerx Ltd. get a toehold in China with its hepatitis C virus (HCV) treatment BL-8030.

SHANGHAI, China – While the presidents from the U.S. and China have met in a summit to address human rights and cyber-attack issues, it's become clear that U.S. biopharmaceutical firms have not been immune to targeted hacking out of China. These efforts may have yielded valuable data from clinical trials or drug registration applications.

SHANGHAI – While the presidents from the U.S. and China have met in a summit to address human rights and cyber-attack issues, it's become clear that U.S. biopharmaceutical firms have not been immune to targeted hacking out of China. These efforts may have yielded valuable data from clinical trials or drug registration applications.